GLP-1 receptor agonists like semaglutide and tirzepatide delay gastric emptying enough to cause regurgitation and aspiration under anesthesia, requiring mandatory discontinuation before surgery — a critical update for all surgeons.
Aspiration risk under anesthesiaGLP-1 agonists delay gastric emptying enough that patients may have stomach contents despite standard fasting protocols
What the researchers found
GLP-1 receptor agonists cause delayed gastric emptying that increases aspiration risk under anesthesia. Discontinuation before surgery is imperative, and SGLT-2 inhibitors pose a separate risk of severe diabetic ketoacidosis perioperatively.
Why it matters
Millions of patients are now taking GLP-1 agonists, and many will undergo surgery. Failure to stop these drugs before anesthesia can cause life-threatening aspiration. Every surgeon — not just endocrinologists — needs to know this.
The numbers in context
Review covers semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), dapagliflozin (Farxiga), and empagliflozin (Jardiance) among others.
How the study worked
Narrative review of current literature and clinical guidelines on perioperative management of diabetes/weight loss medications (GLP-1 RAs, SGLT-2i), antithrombotic medications, and RA immunosuppressants for surgical procedures.
Who was studied
Surgical patients on GLP-1 RAs and related medications
What this study cannot tell us
Narrative review without systematic methodology. Perioperative guidelines are still evolving as more real-world data accumulates. The optimal timing of drug discontinuation before surgery varies by drug and hasn't been definitively established for all agents.
How to read the evidence
Moderate evidence from clinical guidelines and case reports. The aspiration risk mechanism is well-established pharmacologically; specific discontinuation timelines are still being refined.
When this study was published
Published in 2024; addresses the urgent need for perioperative awareness as GLP-1 drug use has surged.
The bigger picture
The rapid adoption of GLP-1 agonists for weight loss has outpaced awareness of their perioperative implications. Anesthesia societies worldwide are now issuing guidelines on pre-surgical GLP-1 management. This review ensures surgical specialties beyond general surgery are prepared.
Questions still open
- What is the minimum fasting time needed for patients on GLP-1 agonists before safe anesthesia?
- Can point-of-care gastric ultrasound reliably assess residual gastric volume in GLP-1 users before surgery?
- Should regional anesthesia be preferred over general anesthesia for patients who can't safely discontinue GLP-1 drugs?
Common questions
Why do GLP-1 drugs need to be stopped before surgery?
How far in advance should I stop my GLP-1 medication before surgery?
Read the original research
Update on Perioperative Medication Management for the Hand Surgeon: A Focus on Diabetes, Weight Loss, Rheumatologic, and Antithrombotic Medications.
The Journal of hand surgery, 49(10), 1012-1020
Citation
Xu, Wen; Schmiesing, Cliff; Chang, James. (2024). Update on Perioperative Medication Management for the Hand Surgeon: A Focus on Diabetes, Weight Loss, Rheumatologic, and Antithrombotic Medications.. The Journal of hand surgery, 49(10), 1012-1020. https://doi.org/10.1016/j.jhsa.2024.05.018